Abstract:
The invention concerns a medicine for treatment of prostate cancer and a corresponding treatment method. The medicine can be supplied to a prostate tumor through the bloodstream, contains an active component and a binding component as well as ultrasound microbubbles. The binding component includes coupling molecules that specifically bind to a determined target molecule formed in the endothelium of tumor-associated blood vessels and that is typical of the tumor or the tumor stage. The active component contains at least one chemotherapeutic substance. The coupling molecules are bound to the outside of the microbubbles and active substance molecules are likewise bound to the outside of the microbubbles or are enclosed by the microbubbles.
Abstract:
In this device and the associated method, a connection unit that can be attached to an arm bearing an x-ray source and an x-ray receiver is fashioned such that said connection unit compensates for a pivot movement of the arm so that a compression unit arranged at the connection unit remains stationary during a pivot movement.
Abstract:
In a method and apparatus for detecting tumorous cell tissue in a gastrointestinal tract, electromagnetic radiation is emitted in a locally defined manner from an endoscope onto cell tissue and, after deactivation of the radiation, the decay of the inherent fluorescence intensity of the irradiated cell tissue, excited by the electromagnetic radiation, is detected, with temporal and spectral resolution and with a known scanning rate for at least one wavelength. From the intensity measurement values obtained in this manner, the difference autocorrelation function of the intensity decay is determined, from which a fractal dimension for the irradiated cell tissue is determined. The value of the fractal dimension is used to classify the irradiated cell tissue as to a degree to which the cell tissue is tumorous.
Abstract:
In a screening test method, and a device for implementing the screening test method, a diagnostic substance is provided that contains at least one biomarker connected with at least one ferromagnetic particle, the biomarker binding specifically to a target molecule that is formed by specific pathological prostrate tissue. The diagnostic substance is administered to the blood stream of a patient. A magnetometer is used to detect enrichment of the ferromagnetic particle in the prostrate, as an indicator of a level of the specific pathological prostrate tissue.
Abstract:
A urological x-ray workstation has an x-ray source and an x-ray receiver that are respectively supported on device retainers of a device carrier located at the longitudinal side of a patient positioning table such that they can be positioned opposite one another and independently of one another in various positions on an orbit proceeding around a common center in a working plane oriented perpendicular to the longitudinal axis.
Abstract:
In a method for image guided prostate cancer needle biopsy, a first registration is performed to match a first image of a prostate to a second image of the prostate. Third images of the prostate are acquired and compounded into a three-dimensional (3D) image. The prostate in the compounded 3D image is segmented to show its border. A second registration and then a third registration different from the second registration is performed on distance maps generated from the prostate borders of the first image and the compounded 3D image, wherein the first and second registrations are based on a biomechanical property of the prostate. A region of interest in the first image is mapped to the compounded 3D image or a fourth image of the prostate acquired with the second modality.
Abstract:
In a method for imaging a prostate tumor in which a contrast agent that can be distributed via the circulatory system is administered to the patient, the contrast agent contains at least one type of biomarkers which are bound to a ferromagnetic particle and specifically bind to a target molecule typical of the tumor and formed within the tumor or in a tissue adjacent to the tumor. The imaging ensues with the use of magnetic resonance tomography.
Abstract:
The invention relates to a mobile C-arm system (C1), at least comprising at least three wheels, at least two wheels each having an electric motor, wherein the electric motor has a stator (S) and a rotor (R), the stator (S) being connected to a wheel suspension (T) of the wheel and the rotor (R) being surrounded peripherally by a running wheel (L).
Abstract:
The invention relates to a method and to an apparatus for recognizing tumorous living cell tissue. It furthermore relates to a method and to an apparatus for recognizing tumorous cell tissue at collected living cell tissue samples. In the method, electromagnetic radiation is emitted with local definition onto cell tissue by a radiation source and, after deactivation of the radiation source, the decay behavior of the inherent fluorescence intensity of the cell tissue excited by the electromagnetic radiation is detected at the cell tissue in a time resolved and spectrally resolved manner at known sampling rate(s) for at least one wavelength using a detector. The difference autocorrelation function C(t) of the intensity decay behavior is determined using the determined measured intensity values, the fractal dimension DF for the respective irradiated cell tissue is calculated from this and the value of the fractal dimension DF is used for a classification with respect to a presence of a tumor in the respective irradiated cell tissue.
Abstract:
In a screening test method, and a device for implementing the screening test method, a diagnostic substance is provided that contains at least one biomarker connected with at least one ferromagnetic particle, the biomarker binding specifically to a target molecule that is formed by specific pathological prostrate tissue. The diagnostic substance is administered to the blood stream of a patient. A magnetometer is used to detect enrichment of the ferromagnetic particle in the prostrate, as an indicator of a level of the specific pathological prostrate tissue.